Show Summary Details
Page of

Cutaneous reactions to drugs 

Cutaneous reactions to drugs

Chapter:
Cutaneous reactions to drugs
Author(s):

Peter S. Friedmann

and Eugene Healy

DOI:
10.1093/med/9780199204854.003.2316_update_001

Update:

Pathophysiology—discussion of HLA associations for generation of drug hypersensitivity reactions.

Clinical manifestations—new section on systemic hypersensitivity reactions: drug reaction with eosinophilia and systemic symptoms (DRESS).

Updated on 28 Nov 2013. The previous version of this content can be found here.
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2015. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy).

date: 18 August 2017

Adverse drug reactions (ADR) are responsible for about 5% of all hospital admissions, and 10 to 20% of hospital inpatients develop ADRs, many of which involve the skin. ADRs are classified into five groups: (1) type A (augmented)—the most common form of drug reaction, and predictable from the normal pharmacological effects of the drug or its metablite; (2) type B (bizarre)—are not predictable and reflect patient individuality; most cutaneous drug reactions, including hypersensitivity reactions, are of this type; (3) type C (chemical)—can often be predicted from the structure of the drug or its metabolites; some cutaneous reactions are of this type; (4) type D (delayed)—e.g. teratogenicity; (5) type E (end of dose)—withdrawal reactions....

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.